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Nonhormonal drugs probably account for only a small proportion of human cancer but have contributed many valuable insights into carcinogenic
mechanisms. The antineoplastics, radiopharmaceuticals, and a few other agents account for most of the known drug-induced cancer. A number of
other agents are under suspicion, usually due to studies in laboratory animals or to preliminary clinical or epidemiologic observations. This group
includes some drugs in widespread use such as clofibrate and cimetidine. For a few drugs that are carcinogenic in animals, such as dapsone and
isoniazid, epidemiologic studies have shown little to no evidence of carcinogenicity. Recent experimental studies have shown tumor promotion by
the commonly used antidepressants amitriptyline and fluoxetine and some antihistamines, which deserve epidemiologic investigation of cancer risk.
Some drugs may also protect against cancer, as suggested by the lower risk of colorectal cancer among regular users of nonsteroidal antiinflamma-
tory drugs. Pharmacoepidemiologic studies must take into account possible confounding by the original conditions for which drugs were taken and
the typically long latency period of drug-induced cancer. Improved postmarketing surveillance, continued routine case-control surveillance, and ad
hoc case-control and cohort studies are needed to evaluate drugs already in use as well as newly introduced agents. - Environ Health Perspect
103(Suppl 8):191-196 (1995)
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Introduction
Drugs are given at doses sufficient to
achieve a physiologic effect, but often there
are acute and sometimes chronic side
effects. One of the serious late conse-
quences of certain medications, including
nonhormonal agents, is the development of
cancer, although these exposures con-
tribute to only a small proportion of
human cancer. This review groups nonhor-
monal drugs into agents classified as
human carcinogens by the International
Agency for Research on Cancer (IARC)
(1); agents suspected ofbeing human car-
cinogens; agents with some evidence for
carcinogenicity in laboratory animals but
with epidemiologic studies showing little
or no carcinogenic risk in humans; and
drugs that have recently come to attention
because of their tumor-promoting or
tumor-inhibiting abilities.
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Known Human Carcinogens
Antineoplastics, radiopharmaceuticals, and a
few other agents account for most of the
known drug-induced cancers (Table 1) (1).
Alkylating agents used in cancer chemother-
apy are associated with subsequent develop-
ment of acute nonlymphocytic leukemia
and, to a lesser extent, lymphoma. Cyclo-
phosphamide has been linked to bladder
cancer (2), and concern has been raised gen-
erally about the long-term risk of solid
tumors after using alkylating agents (2).
IARC has classified alkylating agents, as a
group, as is carcinogenic to humans,
although research continues to quantify the
risk for specific agents. These risks and pos-
sible substitutions by other agents must be
weighed against the antineoplastic benefits.
The carcinogenic effects of drugs may
be identified shortly after use, such as with
chlornaphazine, a drug used more than
two decades ago to treat polycythemia vera
and certain cancers. Chlornaphazine was
metabolized to f-naphthylamine, a potent
bladder carcinogen (3,4). A striking inci-
dence ofbladder cancer was quickly recog-
nized and the drug was withdrawn from
use. Usually, however, more time elapses
Table 1. Nonhormonal drugs classified as human carcinogens.a
Class Agent Cancer
Analgesics and antiinflammatory agents Mixtures containing phenacetin Kidney, lower urinary tract
Antineoplastic agents Chlorambucil Leukemia
Chlornaphazine Bladder
Cyclophosphamide Bladder, leukemia
Melphalen Leukemia
Myleran Leukemia
MOPP (and other combined chemo- Leukemia, lymphoma
therapy including alkylating agents)
Thiotepa Leukemia
Treosulphan Leukemia
Methyl-CCNU Leukemia
Dermatologic agents Arsenic salts Skin
Coal tars Skin
PUVA(8-methoxypsoralen and Skin
ultraviolet radiation)
Immunosuppressants Azathioprine Lymphoma, skin, other
Cyclosporin A Lymphoma, other
Radiopharmaceuticals Radioactive phosphorus Acute myeloid leukemia
Radium Osteosarcoma, nasal sinus
Thorotrast Liver
a Data from IARC (1).
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before carcinogenic effects ofmedications
are recognized.
The other drugs known to be carcino-
genic in humans include analgesic mixtures
containing phenacetin, some dermatologic
agents, immunosuppressants, and radio-
pharmaceuticals. Long-term heavy use of
mixtures containing phenacetin has been
linked to cancers ofthe renal pelvis, ureter,
and bladder (2,5-9). This drug has been
withdrawn, but the findings raise concern
about the commonly used acetaminophen,
which is metabolized to phenacetin. Certain
dermatologic agents such as inorganic
arsenic (Fowler's solution), coal tar oint-
ments, and PUVA (8-methoxypsoralen
plus ultraviolet radiation) increase the risk
ofskin cancer (2,10,11). Immunosuppres-
sants such as azathioprine and cyclosporin
A are associated with increased risk ofnon-
Hodgkin's lymphoma, skin cancer, and cer-
tain other tumors, especially when the drugs
are used with organ transplantation (1,2).
These findings have contributed to evidence
that immunosuppression by various mecha-
nisms predisposes the development ofthese
tumors. In addition, radiopharmaceuticals
increase the risk ofcancer by continuing to
emit radiation when sequestered in human
tissue. Thorotrast, for example, once used
as a radiographic contrast medium, has
been linked to certain cancers such as
angiosarcoma ofthe liver (12).
Suspect Human Carcinogens
A number ofother drugs are under suspi-
cion, often because ofmutagenicity or car-
cinogenicity in laboratory animals or
occasionally because ofclinical data that
are insufficient to draw conclusions about
the risk in humans (Table 2). Methoxy-
flurane and phenytoin are suspected of
increasing the risk ofcancer among the off-
spring ofwomen who were exposed during
pregnancy (13-18). Phenytoin use has
been reported in association with lym-
phoma, but the risks, if any, appear small
(14-19). Some drugs in widespread use,
such as aspirin, clofibrate, cimetidine, and
diuretics, are under evaluation. Aspirin has
been linked to kidney cancer in some stud-
ies (2,20) but not all (21), and to non-
Hodgkin's lymphoma in one recent study
(22), while diuretics have been associated
with renal-cell cancer (23-30). Clofibrate,
a cholesterol-lowering drug, has been related
to cancers ofthe lung, liver, and intestines
(31), but the negative results from more
recent studies have been reassuring (2).
Cimetidine, used widely for treatment of
peptic ulcer, has been related to stomach
Table 2. Nonhormonal drugs suspected of being human carcinogens.
Class Agent Cancer
Anesthetics Methoxyflurane Wilms' tumor
Nonsteroidal Aspirin Kidney, non-Hodgkin's lymphoma
antiinflammatory drugs Phenylbutazone Leukemia
Antibacterial drugs Chloramphenicol Leukemia, softtissue sarcoma
Antineoplastic agents Bischloroethyl nitrosoureas (BCNU) Leukemia
Doxorubicine Leukemia
Mechlorethamine Leukemia
Prednimustine Leukemia
Procarbazine Leukemia
Antifungal agents Griseofulvin Thyroid
Metronidazole Lung
Drugs fortreating anemia Iron-dextran complexes Softtissue sarcoma
Drugs fortreating Clofibrate Lung, liver, intestines
cardiovascular disorders
Drugs fortreating CNS disorders Phenobarbital Lung, lymphoma
Phenytoin Lymphoma, neuroblastoma, soft
tissue sarcoma
Drugs fortreating thyroid disorders Propylthiouracil Breast
Thiourea
Drugs fortreating ulcers Cimetidine Stomach, lymphoma
CNS, central nervous system.
cancer (1), but the association may be con-
founded by use ofthe drug to treat symp-
toms of incipient stomach cancer. When
use within 1 year ofdiagnosis is ignored,
the association fades (32). It is crucial that
the safety concerns over these commonly
used drugs are resolved.
The strength ofthe evidence for human
carcinogenicity varies for the drugs in
Table 2. For example, several reports indi-
cate an association between chlorampheni-
col use and leukemia (33,34), although the
risk, if any, appears small, but only one
report relates chloramphenicol to soft tis-
sue sarcoma, with some questions about
the quality of the self-reported exposure
data (35). An association between iron-
dextran injections and soft tissue sarcoma is
based on case reports (36,37), while suspi-
cions about alum-adsorbed allergenic
extracts are not supported by analysis of
time trends forsoft tissue sarcomas (38).
With more research and longer follow-
up periods, some ofthe drugs in this group
may eventually be classified as carcinogens
or may be exonerated. For example, a recent
report on the long-term sequelae ofalkylat-
ing agents showed a 13.4-fold increased
risk of acute nonlymphocytic leukemia
among persons following prednimustine
treatment for non-Hodgkin's lymphoma,
with risks reaching about 20-fold among
patients receiving higher doses (39). Since
the drug is chemically allied to chlorambu-
cil, which has leukemogenic properties, one
could argue that the drug should now be
classified as a human carcinogen based on
this one study. On the other hand, several
studies have shown no increased cancer risk
following treatment with metronidazole
(40,41), an antifungal medication that is
both mutagenic and carcinogenic in experi-
mental studies (42-44). If these results
persist after additional follow-up to exclude
increased risk after long latency, it would
appear that metronidazole does not pose a
carcinogenic risk to humans.
Drugs Evaluated with
Little or No Evidence of
Human Carcinogenicity
A few drugs that are mutagenic or carcino-
genic in animals reveal little to no evidence
ofhuman carcinogenicity by epidemiologic
studies (Table 3). Dapsone, a drug used to
treat Hansen's disease (leprosy), malaria,
and certain other diseases (45), induced
mesenchymal tumors of the spleen and
thyroid tumors in rats (46-49) and has
been linked to cancer in a few case reports
(2). Several cohort studies of patients
treated for Hansen's disease, however, show
no elevated riskofcancer (50-53).
Isoniazid, a drug used in tuberculosis
treatment and prophylaxis, is mutagenic
and carcinogenic, causingpulmonary tumors
in mice (2,54). Concern over possible
Table 3. Nonhormonal drugs with studies showing
some evidence of carcinogenicity in animals but with
little or no evidence for human cancer risk.
Class Agent
Antibacterial drugs Dapsone
Isoniazid
Psychotropic drugs Diazepam
Drugs to treatcardiovascular disorders Reserpine
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carcinogenicity in humans was raised by
the experimental data and by an epidemio-
logic report ofan association with bladder
cancer (55-57) and case reports of lung
cancer (59). Several other studies, however,
found no increased risk ofbladder cancer
(60-63), including a large study ofapproxi-
mately 3000 cases and 6000 controls (63).
Other studies have shown no excess oflung
cancer or other malignancies (64-67).
Reserpine, an antihypertensive medica-
tion, increases secretion ofprolactin, a pitu-
itary hormone that affects breast tissue
differentiation, and induces mammary
tumors in mice and rats (2). These findings
led to an extensive evaluation ofthe role of
reserpine in the etiology ofbreast cancer in
women. In 1974, three studies reported
associations between reserpine and breast
cancer with relative risk estimates ranging
from 2.0 to 3.5 (68-70). By 1987, IARC
counted 17 case-control studies and 3
cohort studies on the relationship between
reserpine and breast cancer (2). The relative
risk estimates ranged from 0.6 to over 3, but
studies with the strongest methodologies
showed little or no evidence ofincreased
risk. In a large study ofapproximately 1400
breast cancer cases and 1250 controls, reser-
pine use was associated with a nonsignificant
20% excess risk (71). The weight ofthe evi-
dence to date suggests that reserpine has little
or no effect on the risk of breast cancer.
Nonetheless, a recent study suggested an
excess risk among long-term users, pointing
to the need forcontinued follow-up (71).
The tranquilizer diazepam enhances the
growth of mammary tumors in rats (72)
and has been suspected ofincreasing the risk
of breast cancer and its progression (73).
Epidemiologic studies have found no posi-
tive relation with breast cancer risk (74-78)
orwith the extent ofdisease and lymph node
involvement (79), and the possibility ofa
protective effect has been suggested (79).
Promoters and
Protective Agents
Some commonly used antidepressants,
amitriptyline (Elavil) and fluoxetine
(Prozac), and antihistamines have recently
been suggested to be tumor promoters in
experimental studies (Table 4). In particu-
lar, amitriptyline and fluoxetine stimulated
growth of mammary fibrosarcomas in
rats fed dimethylbenzanthracene (80).
Other tricyclic analogues ofamitriptyline,
clomipramine and desipramine, exhibited
the same properties (81,82). Also, several
antihistamines enhanced melanoma and
fibrosarcoma in mouse in vitro assays (83).
Only limited epidemiologic data are avail-
able, but one cohort study involving Kaiser
Permanente members showed no excess
cancer among amitriptyline users (84).
Further epidemiologic evaluation is needed,
given thewidespread use ofthese drugs.
Some drugs may protect against cancer,
as suggested by the lower risk ofcolorectal
cancer and polyps among regular users of
nonsteroidal antiinflammatory drugs
(NSAID) (85-96). Experimental studies
have shown inhibition ofcolorectal cancer
and adenomas (97-100), possibly due to
inhibition of the enzyme cyclooxygenase,
which controls synthesis ofprostaglandins
that may increase cell proliferation and
tumor growth (101-104). Case-reports
(105-107) and two randomized trials
(86,87) suggested that the NSAID sulindac
caused reduction ofthe number and size of
colorectal polyps in patients with familial
adenomatous polyposis. Case-control and
cohort studies, with few exceptions, have
consistently shown regular use ofNSAIDs
to be associatedwith an approximately 50 to
60% reduction of colorectal cancer
(88-96,108). More information is needed
on the dose and frequency ofuse that might
confer protection. The Physicians Health
study did not show any protection with reg-
ular aspirin use (109), but the dose may
have been too low or follow-up too short
(110). The ongoing Women's Health
Study, a randomized trial of 100 mg aspirin
every other day among 40,000 female
health professionals, will have longer fol-
low-up and may clarify whether low-dose
aspirin decreases colorectal cancer incidence
(111). Other trials are in progress to evalu-
ate the effect ofNSAIDs on polyp develop-
ment in high-risk groups such as patients
with familial polyposis or with a past
history ofadenomatous polyps (110,112).
It has been suggested that cimetidine,
suspected ofincreasing stomach cancer risk,
may protect against prostate cancer (113).
Cimetidine and other histamine2 receptor
antagonists may inhibit the binding of
dihyrotestosterone to androgen receptors
and lead to increased serum estradiol
(113). A Danish cohort study of cimeti-
dine users reported no excess of stomach
cancer but less than expected prostate can-
cer incidence after 4 years or more of use
(114). Confirmation is needed to deter-
mine if an opportunity exists for chemo-
prevention of prostate cancer, the most
common malignancy among men.
Conclusion
Identifying carcinogenic drugs is difficult
because of the typically long latent period
ofcancer, the inability to distinguish drug-
induced cancers from those induced by
other agents, possible confounding by the
condition for which drugs were taken, the
widespread and even casual use of.some
drugs, and the general lack of epidemio-
logic surveillance for drug-induced cancer.
Animal and microbial screening tests for
mutagenicity and carcinogenicity must
continue and can help set priorities for epi-
demiologic research, but they must be
interpreted cautiously, particularly with
reference to dose extrapolations. The Food
and Drug Administration should be given
legal authority to require postmarketing
surveillance as part ofthe approval process
for new drugs. Epidemiologic research
should incorporate routine surveillance
through record linkage surveys and case-
control studies such as those pioneered by
the Kaiser prepaid health plan and the Sloan
Epidemiology Unit at Boston University.
Further ad hoc case-control and cohort
studies (with extended follow-up) are
needed to help settle a number ofhypothe-
ses about drug-related cancer, and also to
provide better understanding of carcino-
genic mechanisms. Minimizing or elimi-
nating the use of harmful drugs and
searching for alternatives may prevent
some, albeit a relatively small proportion,
ofhuman cancer.
Table 4. Nonhormonal drugs and cancer: possible promoters and protective agents.
Drug types Agent Action
Promoters
Antidepressants Amitriptyline (Elavil) Promotes fibrosarcomas in mice
Flouxetine (Prozac) and mammary tumors in rats
Antihistamines Astemizole Promotes melanoma and
Loratidine fibrosarcomas in mice
Hydroxyzine Promotes melanoma in mice
Protective agents
Nonsteroidal Aspirin Reduces risk of colorectal polyps
antiinflammatory drugs Piroxicam and cancer in humans
Sulindac
Drugs fortreating ulcers Cimetidine Reduces risk of prostate cancer
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